<img src="https://ml.globenewswire.com/Resource/Download/c63a19fa-f624-43d3-852f-d5956983aef3?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Aprea Logo.jpg" alt="Aprea Therapeutics"/>DOYLESTOWN, Pa., Nov. 05, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and meet with investors at Guggenheim’s 3rd Annual Healthcare Innovation Conference, to be held November 9-11, 2026 in Boston, MA. Presentation Details <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:20%; width:20%; min-width:20%;">Date:</td><td style="max-width:80%; width:80%; min-width:80%;">Monday, November 9, 2026</td></tr><tr><td>Time: </td><td>10:00 am ET</td></tr><tr><td>Webcast link:</td><td>Click <a href="https://www.globenewswire.com/Tracker?data=No8enjtuqJSSCySbzHlTHAz7Eev9xG0gIdOVm7sS94Hvol3tGDD9QB6BKOuW3WUdpiVU0DKEhJ7q9zThk2wPBF7Obqf6xUvDs78fWdw9tXgftcg1S_iGnLX3mGUwjkU5P9j_veKOczMYkodWn6U4vdFTvqAD1RvUawrOPIDf98I=" rel="nofollow" target="_blank" title="here">here</a></td></tr><tr><td> </td><td> </td></tr></table> Those interested in arranging a one-on-one meeting with Dr. Gilad should contact their Guggenheim representative. About Aprea Aprea is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors but to minimize the effect on normal, healthy cells, decreasing the risk of toxicity that is frequently associated with chemotherapy and other treatments. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, colorectal, prostate, and breast cancers. The company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit the company website at <a href="https://www.globenewswire.com/Tracker?data=9R5G2mMDhtTgsdxZSptQmUmiGb8wwKDh0MtonXZHldDoX8ZhYYmAuYOpmVAZNRxO-xYEUBUrgvQEjoLXBVNxKg==" rel="nofollow" target="_blank" title="">www.aprea.com</a>. The Company may use, and intends to use, its investor relations website at <a href="https://www.globenewswire.com/Tracker?data=p9m0d4muJvV7O84p3z-jIw-EdpcsOdjuVK3kpr8NmaahosfHbn5mXlWCWCbBjUKk6IUdPjQyO80oHVazi_2Gv1wIpaa8w7h5gX1AMR1EU40=" rel="nofollow" target="_blank" title="">https://ir.aprea.com/</a> as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Investor and Media Contact: Mike Moyer LifeSci Advisors <a href="https://www.globenewswire.com/Tracker?data=65Ynx8hnpsOlwlmJIzBzSCd9Bto6ivROh9p4gl9S-ya8NQOl8k5IcqzITFkGtxRyfTh94uKpuBO4yQKWuQ_ZcOZ50Y67IM8lOn_CeV5DTv4AajoAk_prhtOdEsr2_ytB" rel="nofollow" target="_blank" title="">mmoyer@lifesciadvisors.com</a> Media Contact: Sean Naughton Ph.D. Russo Partners, LLC <a href="https://www.globenewswire.com/Tracker?data=T3rP3vudNYQxJj1bl2C75Q6qHltRM9aMmYYEhj9ZpVkgZuFUU3sYXRfrVQv95trjVTtZB_hVHFDSUcxGtQXngZcslmKmUsqZKTiwTTt226XtuG5n2UWO1iHFijId7-qHfqdnYPol_c6AdKNUvpsJjfpNmVOqLQ_j5uNaJKxMWD3wMYRp9RFJEYhCAT7nLxczuB2vHOpr2Ul6m2qK8HCEOiFdWoNOgMLDRXjwAeFfvA1MqPv04fWJxHd4p1vq4z_bGhhDoPmqpr-RC65ztzw-U6Ork1zJ9BQo8of_FLmdig7MCfvjI7jkL9OM1EmC14IJ5C1DAKRTSivObosXteti_Q==" rel="nofollow" target="_blank" title="sean.naughton@russopartnersllc.com">sean.naughton@russopartnersllc.com</a> <img alt="" src='https://ml.globenewswire.com/media/YTc0YmI4MzMtODQyOC00ODY1LTk1MmUtMTE3ZWE5MjdkMTYyLTExOTI4NDktMjAyNi0xMS0wNS1lbg==/tiny/Aprea-Therapeutics.png' referrerpolicy='no-referrer-when-downgrade' />

Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn